ET-01

BIOLOGICAL3 trials

Sponsors

Institute of Hematology & Blood Diseases Hospital, China, EdiGene (GuangZhou) Inc.

Conditions

Transfusion Dependent Beta-Thalassaemia

Phase 1

A Safety and Efficacy Study Evaluating ET-01 in Subjects with Transfusion Dependent Β-Thalassaemia

TerminatedNCT04925206

EdiGene (GuangZhou) Inc.Transfusion Dependent Beta-Thalassaemia

Start: 2021-08-17End: 2025-03-12Updated: 2025-03-30

Unknown Phase

Safety and Efficacy Evaluation of ET-01 Transplantation in Subjects With Transfusion Dependent β-Thalassaemia

CompletedNCT04390971

Institute of Hematology & Blood Diseases Hospital, ChinaTransfusion Dependent Beta-Thalassaemia

Start: 2023-02-10End: 2023-03-05Updated: 2026-02-11

A Study to Evaluate the Safety and Efficacy of ET-01 Transplantation in Subjects with Transfusion Dependent Β-Thalassaemia.

TerminatedNCT05752123

EdiGene (GuangZhou) Inc.Transfusion Dependent Beta-Thalassaemia

Start: 2023-02-18End: 2025-03-12Updated: 2025-03-30

Related Papers

Preliminary Safety and Efficacy Results of EDI001: An Investigator Initiated Trial on CRISPR/Cas9-Modified Autologous CD34+ Hematopoietic Stem and Progenitor Cells for Patients with Transfusion Dependent β-Thalassemia

Blood2022-11-158 citations